Overview

* IN8bio ( INAB ) Q3 net loss narrows to $3.9 mln from $7.1 mln last year

* R&D expenses for Q3 decreased due to strategic pause in INB-400 program

* Company expanded INB-100 trial to accelerate enrollment at multiple sites

Outlook

* IN8bio ( INAB ) to present updated INB-200/400 data at SNO Annual Meeting, Nov 19-23, 2025

* Additional INB-619 preclinical data to be presented at ASH Annual Meeting, Dec 6-9, 2025

Result Drivers

* R&D EXPENSES - Expenses fell to $2.1 mln from $3.3 mln due to pause on clinical trial-related activities for the INB-400 program last year and personnel-related costs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$3.85

Income mln

Q3 Basic -$0.85

EPS

Q3 $3.97

Operatin mln

g

Expenses

Q3 -$3.85

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* Wall Street's median 12-month price target for IN8bio Inc ( INAB ) is $7.00, about 76.7% above its November 5 closing price of $1.63

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)